Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans

BACKGROUND: To address the US opioid epidemic, there is an urgent clinical need to provide persons with opioid use disorder (OUD) with effective medication treatments for OUD (MOUD). Formulations of sublingual buprenorphine/naloxone (SL-BUP/NLX) are considered the standard of care for OUD including...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrakis, Ismene, Springer, Sandra A., Davis, Cynthia, Ralevski, Elizabeth, Gu, Lucy, Lew, Robert, Hermos, John, Nuite, Melynn, Gordon, Adam J., Kosten, Thomas R., Nunes, Edward V., Rosenheck, Robert, Saxon, Andrew J., Swift, Robert, Goldberg, Alexa, Ringer, Robert, Ferguson, Ryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802273/
https://www.ncbi.nlm.nih.gov/pubmed/35101115
http://dx.doi.org/10.1186/s13722-022-00286-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802273/
https://www.ncbi.nlm.nih.gov/pubmed/35101115
http://dx.doi.org/10.1186/s13722-022-00286-6

Ejemplares similares